Publications by authors named "Laura V de Paus"
The cannabinoid receptor type 2 (CBR) is a G protein-coupled receptor with therapeutic potential for the treatment of inflammatory disorders. Fluorescent probes are desirable to study its receptor localization, expression and occupancy. Previously, we have reported a photoaffinity probe LEI-121 that stabilized the inactive conformation of the CBR.
View Article and Find Full Text PDFArticle Synopsis
- Researchers have discovered a new cannabinoid receptor (CBR) agonist called LEI-102, used alongside other CBR ligands to understand how these compounds activate the receptor.
- The study reveals important molecular details, including specific residues necessary for CBR activation and the differences in how various ligands reach the receptor's binding site.
- Findings also indicate that LEI-102’s favorable chemical properties allow it to be effective orally in a model of kidney damage caused by chemotherapy, suggesting implications for future drug design targeting GPCRs.